Publication|Videos|October 3, 2024
FSP Partnership: A Foundation for Innovation and Patient-Guided Development
Author(s)PAREXEL
Liz Rogers, VP and Head of Global Site and Study Operations at Pfizer, discusses Pfizer's partnership with Parexel and transition to a functional service provider (FSP) model.
- Transitioning to an FSP model, strategically allocating resources, and leveraging partnerships introduced a more streamlined and efficient model, enhancing resource efficiency and flexibility. The approach has enabled the sponsor (Pfizer) to tap into specialized expertise while maintaining control and oversight of clinical operations.
- Growing core capabilities in site and study management further enhanced site performance and oversight of quality and compliance. Further strengthening relationships with sites is key to the strategy alongside supporting novel recruitment models, shifting to remote monitoring, and focusing on fewer, higher-performing clinical sites.
Related Content
Trending on Applied Clinical Trials Online
1
NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market
2
ACT Brief: Real-Time Trial Infrastructure Gaps, Built-In Data Security, and AI-Enabled CDMO Value
3
Real-Time Clinical Trials: What the FDA's Push Toward Continuous Oversight Means for Sponsors
4
ACT Brief: DIA Leadership and Infrastructure Priorities, Real-Time Data Review Readiness, and CLL Treatment Expansion
5